Defective Mismatch Repair and Benefit from Bevacizumab for Colon Cancer: Findings from NSABP C-08

National Surgical Adjuvant Breast and Bowel Project protocol C-08 tested the worth of adding 1 year of bevacizumab to oxaliplatin-based standard adjuvant chemotherapy regimen in the treatment of stage II/III colon cancer. Although the overall result was negative, the possibility that a molecularly d...

Descripción completa

Guardado en:
Detalles Bibliográficos
Autores principales: Pogue-Geile, Kay, Yothers, Greg, Taniyama, Yusuke, Tanaka, Noriko, Gavin, Patrick, Colangelo, Linda, Blackmon, Nicole, Lipchik, Corey, Kim, Seong Rim, Sharif, Saima, Allegra, Carmen, Petrelli, Nicholas, O’Connell, Michael J., Wolmark, Norman, Paik, Soonmyung
Formato: Artigo
Lenguaje:Inglês
Publicado: Oxford University Press 2013
Materias:
Brief Communication
Acceso en línea:https://ncbi.nlm.nih.gov/pmc/articles/PMC3699439/
https://ncbi.nlm.nih.gov/pubmed/23821759
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/jnci/djt140
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares